Login to Your Account

Professor Dr Hasniza Zaman Huri obtained her PhD and Master in Clinical Pharmacy from the National University of Malaysia and B. Pharm (Honours) from the Universiti Malaya. She is the founder Dean of Faculty of Pharmacy, a newly established and the 13th faculty in the University of Malaya since 1 September 2019, and a Professor of Clinical Pharmacy and Pharmacogenomics in the Department of Clinical Pharmacy and Pharmacy Practice. Professor Dr Hasniza and Type 2 Diabetes is inseparable. Her research covers optimal management, biomarkers, insulin-resistant study, and all areas of Type 2 Diabetes, and clinical pharmacy encompasses associations of drug response and related factors, drug-related problems and pharmaceutical care issues, general biomarkers study, pharmacogenomics-pharmacodynamics study, gene-disease-drug response associations and PK-PD study. She has published more than 80 papers indexed in WOS in her area of expertise. She held various critical administrative posts, among others the Manager of Clinical Investigation Centre (CIC) from 2012-2015 and later appointed as the Director/Head of CIC (2015-2019). CIC, University Malaya Medical Centre is a world-class, reputable and multi-winning clinical trial centre. Under her tenure, CIC has won many accolades at the international levels, procured around 590 clinical trials, and worked with 300 pharmaceutical sponsors and CROs worldwide. CIC recognized as the first Prime Site for Quintiles (now is IQVIA) in Asia, the first Strategic Alliance Site for Parexel Inc in Malaysia and the first Pfizer’s INSPIRE (Investigator Networks, Site Partnerships and Infrastructure for Research Excellence) Site in Malaysia and many more. Previously, Professor Dr Hasniza was also leading the research thrust of UMMC strategic planning. At present, she is also the Honorary Visiting Consultant at CIC and a permanent member of the Drug Control Authority (DCA) Ministry of Health, Malaysia.